Advertisement

In Vitro–Deranged Intestinal Immune Response to Gliadin in Type 1 Diabetes

  1. Renata Auricchio1,
  2. Francesco Paparo1,
  3. Maria Maglio1,
  4. Adriana Franzese1,
  5. Francesca Lombardi1,
  6. Giuliana Valerio1,
  7. Gerardo Nardone2,
  8. Selvaggia Percopo1,
  9. Luigi Greco1 and
  10. Riccardo Troncone1
  1. 1Department of Pediatrics and European Laboratory for the Investigation of Food-Induced Diseases, University “Federico II,” Naples, Italy
  2. 2Department of Experimental Medicine, University “Federico II,” Naples, Italy
  1. Address correspondence and reprint requests to Dr. Renata Auricchio, Dipartimento di Pediatria, Università Federico II, via Sergio Pansini 5, I-80131 Napoli, Italy. E-mail: reauricc{at}tin.it

Abstract

Dietary gluten has been associated with an increased risk of type 1 diabetes. We have evaluated inflammation and the mucosal immune response to gliadin in the jejunum of patients with type 1 diabetes. Small intestinal biopsies from 17 children with type 1 diabetes without serological markers of celiac disease and from 50 age-matched control subjects were examined by immunohistochemistry. In addition, biopsies from 12 type 1 diabetic patients and 8 control subjects were cultured with gliadin or ovalbumin peptic-tryptic digest and examined for epithelial infiltration and lamina propria T-cell activation. The density of intraepithelial CD3+ and γδ+ cells and of lamina propria CD25+ mononuclear cells was higher in jejunal biopsies from type 1 diabetic patients versus control subjects. In the patients’ biopsies cultured with peptic-tryptic gliadin, there was epithelial infiltration by CD3+ cells, a significant increase in lamina propria CD25+ and CD80+ cells and enhanced expression of lamina propria CD54 and crypt HLA-DR. No such phenomena were observed in control subjects, even those with celiac disease–associated HLA haplotypes. In conclusion, signs of mucosal inflammation were present in jejunal biopsies from type 1 diabetic patients, and organ culture studies indicate a deranged mucosal immune response to gliadin.

Footnotes

    • Accepted March 19, 2004.
    • Received July 29, 2003.
| Table of Contents
Advertisement